← SynDRA
PF-06409577
SynDRA canonical compound SYN1739132 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | PRKAA1 | PRKAB1 | PRKAG1 |
|---|
| Mechanism of action | protein kinase activator |
|---|
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- A89WAM8FBH
- RefChem:202572
- MFCD29917835
- UNII-A89WAM8FBH
- orb1302868
- SCHEMBL15300744
- SCHEMBL29376490
- CHEBI:231658
- FHQXLWCFSUSXBF-UHFFFAOYSA-N
- BDBM237920
- EX-A2599
- s8335
- AKOS030211017
- CCG-267937
- CS-8071
- EBC-499075
- SB18863
- NCGC00506867-01
- BP166583
- BS-15440
- DA-66605
- HY-103683
- PF-6409577
- PF06409577
- T4427
- PF-06409577?
- US9394285, 1
- F532134
- PF-06409577, >=98% (HPLC)
- 6VT
- 6-chloranyl-5-[4-(1-oxidanylcyclobutyl)phenyl]-1H-indole-3-carboxylic acid
Look up PF-06409577 in the interactive SynDRA portal →